Convalescent plasma in Covid-19: Possible mechanisms of action.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible of the coronavirus disease 2019 (COVID-19) pandemic. Therapeutic options including antimalarials, antivirals, and vaccines are under study. Meanwhile the current pandemic has called attention over old therapeutic tools to tr...
- Autores:
- Tipo de recurso:
- Fecha de publicación:
- 2020
- Institución:
- Universidad del Rosario
- Repositorio:
- Repositorio EdocUR - U. Rosario
- Idioma:
- eng
- OAI Identifier:
- oai:repository.urosario.edu.co:10336/24587
- Acceso en línea:
- https://doi.org/10.1016/j.autrev.2020.102554
https://repository.urosario.edu.co/handle/10336/24587
- Palabra clave:
- ACE-2 receptor
COVID-19
Convalescent plasma
Coronavirus
Cytokines
Intravenous immunoglobulins
Neutralizing antibodies
SARS-Cov-2
- Rights
- License
- Abierto (Texto Completo)
id |
EDOCUR2_b480dbe01d2eb67b8456ac685a2133b1 |
---|---|
oai_identifier_str |
oai:repository.urosario.edu.co:10336/24587 |
network_acronym_str |
EDOCUR2 |
network_name_str |
Repositorio EdocUR - U. Rosario |
repository_id_str |
|
spelling |
11105414856001022961735600383619336003143448f-dab7-4338-8665-9d38661461758d2fbe92-da8c-46a5-ab8d-8b5ea2cd1d5f5224970152483526600d3968e45-396a-404d-94c5-bfb4bbcb454215d20733-4d96-4082-b857-2d58264922aecb44c18d-c693-4ba5-ba89-8993a5634ee0ef6fa7cf-59f5-4c86-bc53-d389160d7ddf19474778600531672886002020-06-11T13:20:49Z2020-06-11T13:20:49Z2020Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible of the coronavirus disease 2019 (COVID-19) pandemic. Therapeutic options including antimalarials, antivirals, and vaccines are under study. Meanwhile the current pandemic has called attention over old therapeutic tools to treat infectious diseases. Convalescent plasma (CP) constitutes the first option in the current situation, since it has been successfully used in other coronaviruses outbreaks. Herein, we discuss the possible mechanisms of action of CP and their repercussion in COVID-19 pathogenesis, including direct neutralization of the virus, control of an overactive immune system (i.e., cytokine storm, Th1/Th17 ratio, complement activation) and immunomodulation of a hypercoagulable state. All these benefits of CP are expected to be better achieved if used in non-critically hospitalized patients, in the hope of reducing morbidity and mortality.application/pdfhttps://doi.org/10.1016/j.autrev.2020.1025541873-0183https://repository.urosario.edu.co/handle/10336/24587engElsevier BV102554102554Autoimmunity reviewsAutoimmunity reviews, ISSN:1873-0183 (2020); pp. 102554-102554Abierto (Texto Completo)http://purl.org/coar/access_right/c_abf2instname:Universidad del Rosarioreponame:Repositorio Institucional EdocURACE-2 receptorCOVID-19Convalescent plasmaCoronavirusCytokinesIntravenous immunoglobulinsNeutralizing antibodiesSARS-Cov-2Convalescent plasma in Covid-19: Possible mechanisms of action.articleArtículohttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_6501Rojas Quintana, Manuel EduardoRodríguez Velandia, Yhojan AlexisAcosta Ampudia, Yeny YasbleidyCamacho, BernardoGallo, Juan EstebanRojas-Villarraga, AdrianaRamírez Santana, Heily CarolinaDiaz-Coronado, Juan CManrique, RubenMantilla, Ruben DShoenfeld, YehudaAnaya, Juan-ManuelMonsalve Carmona, Diana Marcela10336/24587oai:repository.urosario.edu.co:10336/245872021-10-06 16:52:40.122https://repository.urosario.edu.coRepositorio institucional EdocURedocur@urosario.edu.co |
dc.title.spa.fl_str_mv |
Convalescent plasma in Covid-19: Possible mechanisms of action. |
title |
Convalescent plasma in Covid-19: Possible mechanisms of action. |
spellingShingle |
Convalescent plasma in Covid-19: Possible mechanisms of action. ACE-2 receptor COVID-19 Convalescent plasma Coronavirus Cytokines Intravenous immunoglobulins Neutralizing antibodies SARS-Cov-2 |
title_short |
Convalescent plasma in Covid-19: Possible mechanisms of action. |
title_full |
Convalescent plasma in Covid-19: Possible mechanisms of action. |
title_fullStr |
Convalescent plasma in Covid-19: Possible mechanisms of action. |
title_full_unstemmed |
Convalescent plasma in Covid-19: Possible mechanisms of action. |
title_sort |
Convalescent plasma in Covid-19: Possible mechanisms of action. |
dc.subject.keyword.spa.fl_str_mv |
ACE-2 receptor COVID-19 Convalescent plasma Coronavirus Cytokines Intravenous immunoglobulins Neutralizing antibodies SARS-Cov-2 |
topic |
ACE-2 receptor COVID-19 Convalescent plasma Coronavirus Cytokines Intravenous immunoglobulins Neutralizing antibodies SARS-Cov-2 |
description |
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible of the coronavirus disease 2019 (COVID-19) pandemic. Therapeutic options including antimalarials, antivirals, and vaccines are under study. Meanwhile the current pandemic has called attention over old therapeutic tools to treat infectious diseases. Convalescent plasma (CP) constitutes the first option in the current situation, since it has been successfully used in other coronaviruses outbreaks. Herein, we discuss the possible mechanisms of action of CP and their repercussion in COVID-19 pathogenesis, including direct neutralization of the virus, control of an overactive immune system (i.e., cytokine storm, Th1/Th17 ratio, complement activation) and immunomodulation of a hypercoagulable state. All these benefits of CP are expected to be better achieved if used in non-critically hospitalized patients, in the hope of reducing morbidity and mortality. |
publishDate |
2020 |
dc.date.accessioned.none.fl_str_mv |
2020-06-11T13:20:49Z |
dc.date.available.none.fl_str_mv |
2020-06-11T13:20:49Z |
dc.date.created.spa.fl_str_mv |
2020 |
dc.type.eng.fl_str_mv |
article |
dc.type.coarversion.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
dc.type.coar.fl_str_mv |
http://purl.org/coar/resource_type/c_6501 |
dc.type.spa.spa.fl_str_mv |
Artículo |
dc.identifier.doi.none.fl_str_mv |
https://doi.org/10.1016/j.autrev.2020.102554 |
dc.identifier.issn.none.fl_str_mv |
1873-0183 |
dc.identifier.uri.none.fl_str_mv |
https://repository.urosario.edu.co/handle/10336/24587 |
url |
https://doi.org/10.1016/j.autrev.2020.102554 https://repository.urosario.edu.co/handle/10336/24587 |
identifier_str_mv |
1873-0183 |
dc.language.iso.none.fl_str_mv |
eng |
language |
eng |
dc.relation.citationEndPage.none.fl_str_mv |
102554 |
dc.relation.citationStartPage.none.fl_str_mv |
102554 |
dc.relation.citationTitle.none.fl_str_mv |
Autoimmunity reviews |
dc.relation.ispartof.spa.fl_str_mv |
Autoimmunity reviews, ISSN:1873-0183 (2020); pp. 102554-102554 |
dc.rights.coar.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
dc.rights.acceso.spa.fl_str_mv |
Abierto (Texto Completo) |
rights_invalid_str_mv |
Abierto (Texto Completo) http://purl.org/coar/access_right/c_abf2 |
dc.format.mimetype.none.fl_str_mv |
application/pdf |
dc.publisher.spa.fl_str_mv |
Elsevier BV |
institution |
Universidad del Rosario |
dc.source.instname.spa.fl_str_mv |
instname:Universidad del Rosario |
dc.source.reponame.spa.fl_str_mv |
reponame:Repositorio Institucional EdocUR |
repository.name.fl_str_mv |
Repositorio institucional EdocUR |
repository.mail.fl_str_mv |
edocur@urosario.edu.co |
_version_ |
1814167742393090048 |